Business
Anika is a global joint-preservation company focused on early-intervention orthopedic care, OA pain management, regenerative solutions, and hyaluronic-acid technology.
Anika revenue fell 5.9% to $112.8M, the net loss narrowed to $10.9M, and free cash flow turned positive.
The read at a glance✓ Audited against SEC data
- Business mix — Joint preservation and HA productsNote
- Revenue — Revenue fell 5.9% to $112.8MWatch
- Profitability — Net loss narrowed 80.7%Note
- Cash — Free cash flow turned positiveOK
- Balance sheet — Equity fell 6.8%Watch
- Insiders — 2 buys / 0 sellsOK
- Accounting — Altman-Z grey; EQ safeNote
Where the revenue comes from
Fiscal 2025, as Anika Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- OEM Channel$64.4M
- Commercial Channel$48.4M
Leadership changes
From Anika Therapeutics, Inc.'s own filings, the day they're filed.
- Anne Nunes · Chief Operations Officer · departureeff. 2025-04-25
- Michael Levitz · departureeff. 2024-06-03
- Jeffery S. Thompson · Directors · departureeff. 2024-02-24
Latest filings
- 10-Q · Quarterly report2026-07-29
- 8-K · Company announcement2026-07-29
- 8-K · Company announcement2026-07-14
- 8-K · Company announcement2026-06-23
- 10-Q · Quarterly report2026-04-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Anika Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.